Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.
Kizaki
M
M
Muto
A
A
Kinjo
K
K
Ueno
H
H
Ikeda
Y
Y
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010087:Oxides / Q000009:adverse effects / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000077237:Arsenic Trioxide